Industry Veteran Joins Health Technology
Pioneer to Bring Prescription Digital Therapeutics for Type 2
Diabetes and other Cardiometabolic Conditions to Market
Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital
therapeutics (PDT) company developing a novel form of cognitive
behavioral therapy (CBT) to address the root causes of
cardiometabolic diseases, announced today that Diane Gomez-Thinnes
joined the company as Chief Commercial Officer starting October 26,
2022.
Gomez-Thinnes brings more than two decades of experience in the
healthcare industry, leading the commercialization and launch of
products spanning the medical device, prescription medicines and
consumer health sectors for companies including Johnson &
Johnson and Galderma, where she served as President of U.S.
Operations.
“We could not be more pleased to welcome such an accomplished
and well-respected executive to the Better Therapeutics team,” said
Frank Karbe, CEO of Better Therapeutics. “Diane has an extensive
track record of building and leading highly successful commercial
businesses, in areas including first-of-kind medical devices. As we
look to launch the first prescription digital therapeutic for type
2 diabetes, if the FDA authorizes BT-001 for marketing, it will be
Diane who helps us write the playbook for what a successful launch
in this new and promising space looks like.”
At Galderma, Gomez-Thinnes led the company’s largest U.S.
business in which she delivered double digit growth while playing a
leadership role during a transformative period for the company.
During her tenure, she directed the launch of more than 20 products
including innovative drug delivery technology, a refreshed consumer
product line, and new aesthetics products with a focus on
data-informed treatments. Prior to Galderma, Gomez-Thinnes spent 17
years at Johnson & Johnson, ultimately serving as Worldwide
President for Mentor, where she led the return of that business to
a #1 global leadership position through a refreshed product
pipeline, a new digital customer experience solution, and in-market
commercial partnerships.
Gomez-Thinnes joins Better Therapeutics following the FDA’s
acceptance of the company’s de novo classification request of its
BT-001 prescription digital therapy for type 2 diabetes (T2D) in
adults for review. This comes on the heels of completion of an
encouraging pivotal clinical trial generating positive results for
the company’s lead prescription digital therapeutic. The Better
Therapeutics CBT platform is designed to deliver a novel form of
CBT via a smartphone application to help individuals tackle the
underlying causes of cardiometabolic diseases. In its pivotal trial
for BT-001, T2D patients using the Better Therapeutics platform
with the current standard of care showed improved A1C control
compared to patients only receiving the current standard of care
and were less likely to need additional – and often more costly –
medications to control their disease progression.
“It’s rare to see a company seeking to truly tackle huge health
problems with such an innovative approach that is not only
clinically promising, but which is leveraging advanced technology
to reach patients and potentially improve their quality of life at
a scale that simply was not possible before. Having an opportunity
to set the standard for what prescription digital therapeutics may
accomplish was something that I could not pass up,” said
Gomez-Thinnes. “With prescription digital therapeutics rooted in
CBT, we have a chance to change how we treat epidemic, chronic
conditions like type 2 diabetes, fatty liver disease, heart disease
and more by giving individuals control over their own health. And
we can do this in a way that reaches more patients, especially
those who experience disparities in access to health treatments and
services. I look forward to working with the team to ensure these
investigational therapies make their way to patients and on working
tirelessly to establish Better Therapeutics’ prescription digital
therapies as the market-shifting innovations they have the
potential to become, if authorized by the FDA.”
About BT-001
BT-001 is Better Therapeutics’ investigational prescription
digital therapy for the treatment of T2D. The investigational
therapy is delivered via software that provides a tailored
experience to patients designed to help them address the underlying
causes of T2D by making meaningful, sustainable behavioral changes.
The BT-001 investigational therapy is rooted in the well-studied,
gold standard of behavioral modification therapies, cognitive
behavioral therapy (CBT). While in-person CBT has been used for T2D
and other cardiometabolic conditions before, until now the approach
has not been scalable due to the need to deliver the therapy via a
therapist. If authorized by FDA, BT-001 would be the first
validated, prescription solution for delivering this therapeutic
approach to T2D patients at scale, from their digital devices.
About the Better Therapeutics CBT Platform
Better Therapeutics’ investigational digital therapeutic
platform is designed to deliver a novel form of CBT to help people
with cardiometabolic diseases potentially improve key measures
related to T2D, nonalcoholic fatty liver disease, nonalcoholic
steatohepatitis, hypertension, hyperlipidemia and other
cardiometabolic conditions. By adapting the principles and
mechanisms of CBT, the digital therapeutic platform is designed to
address and modify the cognitive patterns that affect eating habits
and other behavioral factors associated with cardiometabolic
diseases.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT)
company developing a novel form of cognitive behavioral therapy
(CBT) to address the root causes of cardiometabolic diseases. The
company has developed a proprietary platform for the development of
FDA-regulated, software-based solutions for type 2 diabetes, heart
disease and other conditions. The CBT delivered by Better
Therapeutics’ PDT is designed to enable changes in neural pathways
of the brain so lasting changes in behavior become possible.
Addressing the underlying causes of these diseases has the
potential to dramatically improve patient health while lowering
healthcare costs. Better Therapeutics’ clinically validated mobile
applications, if authorized for marketing, are intended to be
prescribed by physicians and reimbursed like traditional
medicines.
For more information visit: bettertx.com
Forward-Looking Statements
Certain statements made in this press release are
“forward-looking statements” within the meaning of the safe harbor
provisions under the United States Private Securities Litigation
Reform Act of 1995. Forward-looking statements are typically
identified by words such as “plan,” “believe,” “expect,”
“anticipate,” “intend,” “outlook,” “estimate,” “forecast,”
“project,” “continue,” “could,” “may,” “might,” “possible,”
“potential,” “predict,” “should,” “would” and other similar words
and expressions, but the absence of these words does not mean that
a statement is not forward-looking. The forward-looking statements
in this press release include, but are not limited to, statements
regarding the results of the completed trial of BT-001 in patients
with type 2 diabetes, Better Therapeutics’ plans and expectations
regarding FDA submissions and the potential for marketing
authorizations, expectations related to the potential benefits of
BT-001 and CBT and their potential treatment applications, Better
Therapeutics’ plans regarding the research and advancement of its
product candidates for additional treatments and expectations
related to the interest of healthcare providers and payers in PDTs,
among others. These forward-looking statements are based on the
current expectations of the management of Better Therapeutics and
are inherently subject to uncertainties and changes in
circumstances and their potential effects and speak only as of the
date of such statement. There can be no assurance that future
developments will be those that have been anticipated. These
forward-looking statements involve a number of risks, uncertainties
or other assumptions that may cause actual results or performance
to be materially different from those expressed or implied by these
forward-looking statements including: risks related to Better
Therapeutics’ business, such as the willingness of the FDA to
authorize PDTs, including BT-001, for commercial distribution and
insurance companies to reimburse their use, market acceptance of
PDTs, including BT-001, the risk that the results of previously
conducted studies will not be interpreted favorably by the FDA or
repeated or observed in ongoing or future studies involving our
product candidates and other risks and uncertainties included under
the header “Risk Factors” in Better Therapeutics’ quarterly report
on Form 10-Q for the quarter ended June 30, 2022 filed with the
Securities and Exchange Commission (SEC) on August 11, 2022, and
those that are included in any of Better Therapeutics’ subsequent
filings with the SEC.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221027005408/en/
Media: Ryan McKenna at Real Chemistry
rmckenna@realchemistry.com
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jul 2023 to Jul 2024